|
Time |
Event |
| 08:00-08:30 |
Registration (Venue: IAS Lobby, G/F) |
| 08:30-09:00 |
Welcoming Remarks
Maria Carrillo (Alzheimer’s Association)
Andrew Cohen (The Hong Kong University of Science and Technology)
David Foster (The Croucher Foundation)
Karl Herrup (The Hong Kong University of Science and Technology) |
| |
Topic #1 – Where We are Now: Amyloid, Tau, Inflammation?
This section is meant as a chance to review and honestly critique the current state of the field. It will address the amyloid cascade hypothesis and discuss the usefulness of secretase- or antibody-based therapies. Anti-inflammatory therapies will also be discussed.
|
| |
Session #1: What are We Talking About Here? |
| 09:00-09:20 |
"Why it
Matters (Lessons from Epilepsy)”
Christophe Bernarde (Aix-Marseille Université)
|
| 09:20-09:50 |
"Alzheimer’s Disease: A Definition”
Bruce Lamb (Indiana University)
|
| 09:50-10:20 |
Synthesis #1: Strengths and Weaknesses of Our Definition |
| 10:20-10:40 |
Group-photo Taking and Coffee Break (Venue:
IAS Lobby, G/F) |
| |
Session #2: To What
Extent Should We Continue to Target Amyloid as Therapy for AD? |
| 10:40-11:00 |
"Background on the Role of Amyloid”
Bryce Vissel (University of Technology Sydney) |
| 11:00-11:20 |
"Presenilin and Alzheimer’s”
Hirotaka Watanabe (Keio University) |
| |
Session #3: To What
Extent Should We Target Tau? |
| 11:20-11:40 |
"Tau-related Mechanisms”
David Morgan (University of South Florida) |
| 11:40-12:00 |
"Immune Approaches to AD Therapy”
Bruce Lamb (Indiana University) |
| 12:00-12:30 |
Synthesis #2: Strengths and Weaknesses of Tau and Amyloid |
| 12:30-14:00 |
Lunch (For speakers only; Venue: China Garden Restaurant) |
| |
Session #4: To What
Extent Should We Target Inflammation? |
| 14:00-14:20 |
"The LC and the Anatomy of AD Inflammation”
Michael Heneka (German Center for Neurodegenerative Diseases) |
| 14:20-14:40 |
"Novel Inflammatory Mediators”
Nancy Ip (The Hong Kong University of Science and Technology) |
| 14:40-15:00 |
"Gene Environment Interactions”
Malu Tansey / Thomas Kukar (Emory University) |
| 15:00-15:20 |
"Microglial Senescence and Cognitive Impairment”
David Morgan (University of South Florida) |
|
15:20-15:40 |
Coffee Break (Venue: IAS Lobby, G/F) |
| 15:40-16:00 |
"TREM2 in Inflammation and AD”
Gary Landreth (Indiana University) |
| 16:00-16:20 |
"Therapeutic Approaches Targeting Inflammation”
Linda Van Eldik (University of Kentucky) |
| 16:20-16:50 |
Synthesis #3: Strengths and Weaknesses of Inflammation Approach |
| |
Topic #2 – What is the Potential of Other Less-studied Areas?
The next session is to identify disease targets that we should be
investing in more heavily. Each is already under exploration, but
attention to their roles in AD etiology may need to be rebalanced. The
goal is to critique the strengths and weaknesses of each as a
contributor to AD and prioritize our follow-up.
|
| |
Session #5:
Metabolism, Diabetes, Lipid Handling / Transport |
| 16:50-17:10 |
"Why Metabolism Matters”
Suzana Herculano-Houzel (Vanderbilt University)
|
| 17:10-17:30 |
"The Contributions of ApoE to AD”
Iliya Lefterov / Rada Koldomovitz (University of Pittsburgh)
|
| 17:30-17:50 |
"The Ways of Using ApoE in AD Therapy”
Guojun Bu (Mayo Clinic College of Medicine & Science) |
| 17:50-18:15 |
Discussion of Metabolism Alternatives |
Back to top |
|
Time |
Event |
| 08:30-08:40 |
Opening Remarks and Review of Day One |
| |
Session #6: Autophagy,
Mitochondria, Growth Factors as Alternative Causes |
| 08:40-09:00 |
"Autophagy”
Randy Nixon (The Nathan Kline Institute for Psychiatric Research) |
| 09:00-09:20 |
"Mitochondrial Function”
Raymond Chang (The University of Hong Kong) |
| 09:20-09:40 |
"Lysosome / Mitochondrial Transport”
Qian Cai (Rutgers University) |
|
09:40-10:00 |
"Vascular Factors”
Donna Wilcock (University of Kentucky) |
| 10:00-10:20 |
Coffee Break (Venue:
IAS Lobby, G/F) |
| 10:20-10:40 |
"Growth Factors and AD”
Margaret Fahnestock (McMaster University) |
| 10:40-11:00 |
Discussion of Vesicle / Growth Factor Alternatives |
| |
Session #7: Epilepsy,
Calcium Imbalances, Myelin, Astrocytes |
| 11:00-11:20 |
"Epilepsy”
Jeff Noebels (Baylor College of Medicine) |
| 11:20-11:40 |
"Myelin”
Andreana Benitez (The Medical University of South Carolina) |
| 11:40-12:00 |
"Calcium Biology”
Grace Stutzmann (Rosalind Franklin University) |
| 12:00-12:20 |
"The Calcium Hypothesis”
Zaven Khachaturian (Alzheimer’s & Dementia) |
| 12:20-14:00 |
Lunch (Self-arranged) |
| |
Session #8: Age, Senescence, DNA
Damage |
| 14:00-14:40 |
"Why Age Matters”
Judith Campisi (The Buck Institute for Research on Aging) |
| 14:40-15:00 |
"DNA Damage as a Driver of the Aging Process ”
Jan Hoeijmakers (Erasmus University Medical Center) |
| 15:00-15:20 |
"CircRNA in the Biology of Brain Aging”
Jiali Li (Kunming Institute of Zoology, Chinese Academy of Sciences) |
| 15:20-16:00 |
"DNA damage, Oligodendrocytes and Cognition”
Karl Herrup (The Hong Kong University of Science and Technology) |
| 16:00-16:20 |
Coffee Break (Venue:
IAS Lobby, G/F) |
| 16:20-16:40 |
Discussion of Aging Alternatives |
| 16:40-17:00 |
Synthesis #4: Strengths and Weaknesses of Alternatives |
| |
Topic #3 – How Shall We Pay for It All?
In doing a full re-assessment of where we are and where we need to
correct our heading, it is important to consider the agencies whose
resources pay for the research – both clinical and basic – that we need
and engage their perspective.
|
| 17:00-17:20 |
"The US NIH Approach to AD Research Funding”
Eliezer Masliah (National Institute on Aging, US National Institutes
of Health) |
| 17:20-17:40 |
"The Asia Approach to AD Research Funding”
Mu-Ming Poo (Institute of Neuroscience, Chinese Academy of Sciences;
Senior Visiting Fellow of HKUST Jockey Club Institute for Advanced Study) |
| 17:40-18:00 |
Open Discussion – the European Approach to AD Funding |
|
18:00 |
Celebratory Banquet (For all participants; Venue: Hung Kee Seafood
Restaurant) |
Back to top |
|
Time |
Event |
| 09:00-09:10 |
Opening Remarks - Summary of Day 2 |
| 09:10-09:30 |
"The Funding of Large-scale Clinical Trials”
Eric Reiman (Arizona State University) |
| 09:30-09:50 |
"The Role of the Pharmaceutical Industry”
Ron DeMattos (Eli Lilly and Company) |
| 09:50-10:10 |
"The Role of Foundation and Private Philanthropy”
Maria Carrillo (Alzheimer’s Association) |
| 10:10-10:30 |
Coffee Break (Venue:
IAS Lobby, G/F) |
| |
Topic #4 - The Final Synthesis: the Path Ahead
This will be the most important session of the three day workshop.
Audience, speakers and panel members will engage in a free exchange of
ideas about the best way to move towards a world where Alzheimer's is a
diminishing threat to our collective health and healthcare systems.
|
| 10:30-12:30 |
Synthesis #5 – What is Our Best Way Forward ? |
| 12:30-13:00 |
Closing Reflections |
Back to top |
